Scalzo Richard William 4
4 · CRESCENT BIOPHARMA, INC. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Crescent BioPharma (CBIO) CFO Richard Scalzo Sells 1,112 Shares
What Happened
Richard William Scalzo, Chief Financial Officer of Crescent BioPharma (CBIO), sold 1,112 shares on June 22, 2026. The weighted-average reported price was $17.99, for aggregate proceeds of $20,005. The sale was a disposition (sale) rather than a purchase and was executed to satisfy tax withholding obligations tied to the settlement of restricted stock units.
Key Details
- Transaction type: Sale (reported as S); executed to cover tax withholding (footnote F1 / code F).
- Date of transaction: 2026-06-22; Form 4 filed 2026-06-23 (timely).
- Price: Weighted average $17.99; individual trade prices ranged $16.88–$18.86 (footnote F2).
- Shares sold: 1,112 — total proceeds reported $20,005.
- Plan/authorization: Sold pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026 (per F1).
- Ownership after transaction: Not disclosed in the provided excerpt of the filing.
- Filing accession: 0001628280-26-044890 (for reference).
Context
- This sale was a routine tax-withholding disposition tied to RSU settlement (RSUs granted December 15, 2025) and executed under a 10b5-1 plan — commonly used to automate planned trades and reduce questions about timing. Such sales are typically administrative (to cover taxes) and do not necessarily indicate a change in the insider’s view of the company.
Insider Transaction Report
Form 4
Scalzo Richard William
Chief Financial Officer
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-06-22$17.99/sh−1,112$20,005→ 20,298 total
Footnotes (2)
- [F1]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Signature
/s/ Barbara Bispham, as attorney-in-fact for Richard William Scalzo|2026-06-23